Semi-Annual Consolidated Statement Of Cash Flows

Oncolys BioPharma Inc. - Filing #7611807

Concept As at
2021-12-31
2021-01-01 to
2021-12-31
2020-01-01 to
2020-12-31
As at
2020-12-31
As at
2019-12-31
Semi-annual consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Subtotal
-1,734,314,000 JPY
-1,457,932,000 JPY
Interest and dividends received
407,000 JPY
781,000 JPY
Interest paid
-4,194,000 JPY
-4,321,000 JPY
Income taxes paid
-3,725,000 JPY
-3,727,000 JPY
Net cash provided by (used in) operating activities
-1,741,827,000 JPY
-1,465,199,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-1,437,000 JPY
-2,700,000 JPY
Proceeds from sale of investment securities
486,000 JPY
JPY
Net cash provided by (used in) investing activities
-942,000 JPY
-37,577,000 JPY
Cash flows from financing activities
Proceeds from long-term borrowings
100,000,000 JPY
100,000,000 JPY
Repayments of long-term borrowings
-122,232,000 JPY
-100,000,000 JPY
Proceeds from issuance of shares
3,085,424,000 JPY
245,505,000 JPY
Purchase of treasury shares
-36,000 JPY
-95,000 JPY
Net cash provided by (used in) financing activities
3,091,384,000 JPY
242,261,000 JPY
Effect of exchange rate change on cash and cash equivalents
38,171,000 JPY
-14,147,000 JPY
Net increase (decrease) in cash and cash equivalents
1,386,785,000 JPY
-1,274,664,000 JPY
Cash and cash equivalents
3,209,635,000 JPY
1,822,850,000 JPY
3,097,514,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.